1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Retinoblastoma Treatment Market 2015-2019

Global Retinoblastoma Treatment Market 2015-2019

  • August 2015
  • -
  • Infiniti Research Limited
  • -
  • 62 pages

About retinoblastoma
Cancer occurs when normal cells transform to evade the regular cell cycle process. Retinoblastoma is a rare eye cancer. It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years. The disease affects the retina and is caused by a mutation in the gene RB1. It usually appears in one eye and gradually spreads to the other. Clinically, retinoblastoma is classified into two: unilateral retinoblastoma, tumor in one eye, and bilateral retinoblastoma, tumor in both the eyes.

Technavio's analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.

Technavio's report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the market segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA

Key Vendors
- Baxter
- Bristol-Myers Squibb
- GlaxoSmithKline
- Spectrum Pharmaceuticals

Other prominent vendors
- BioLineRx
- Cellceutix
- Icon Bioscience
- Neotropix
- RXi Pharmaceuticals
- Recombio

Key market driver
- Increasing public awareness
- For a full, detailed list, view our report

Key market challenge
- Treatment abandonment
- For a full, detailed list, view our report

Key market trend
- Localized treatment approach
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Retinoblastoma Treatment Market 2015-2019
01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Understanding the Disease

06.2 Etiology

06.3 Classification

06.3.1 Bilateral Retinoblastoma

06.3.2 Unilateral Retinoblastoma

06.4 Symptoms

06.5 Diagnosis

06.5.1 Patient Examination

06.5.2 Imaging Tests

06.5.3 Biopsy Tests

06.5.4 Clinical Tests

06.6 Epidemiology

06.7 Staging

06.7.1 Intraocular Staging

06.7.2 Extraocular staging

06.8 Management

06.8.1 Cryotherapy

06.8.2 Chemotherapy

06.8.3 Photocoagulation

06.8.4 Radiation therapy

06.8.5 Surgery

06.8.6 Thermo therapy

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Pipeline Analysis

08.1 Key Information of the Pipeline Candidates

08.1.1 NTX-010

08.1.2 Racotumomab

08.1.3 Kevetrin

08.1.4 BL-8040

08.1.5 Melphalan

08.1.6 RNAi Oligonucleotide for Retinoblastoma

09. Market Segmentation by Therapeutic Class of Drugs

09.1 Alkylating Agents

09.2 Antimetabolites

09.3 Microtubule Inhibitors

09.4 Cytotoxic Antibiotics

09.5 Topoisomerase Inhibitors

09.6 Others

10. Market Segmentation by Disease Status

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2014

19.2.1 Baxter

19.2.2 Bristol-Myers Squibb

19.2.3 GlaxoSmithKline

19.2.4 Spectrum Pharmaceuticals

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 Baxter International Inc.

20.1.1 Key Facts

20.1.2 Business Description

20.1.3 Business Segmentation

20.1.4 Business Strategy

20.1.5 Revenue by Business Segmentation

20.1.6 Revenue by Geographical Segmentation

20.1.7 Key Developments

20.1.8 SWOT Analysis

20.2 Bristol-Myers Squibb

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Key Product Offerings

20.2.4 Revenue by Geography

20.2.5 Business Strategy

20.2.6 Key Information

20.2.7 SWOT Analysis

20.3 GlaxoSmithKline

20.3.1 Business Overview

20.3.2 Business Segmentation

20.3.3 Business Segmentation by Revenue 2012 and 2013

20.3.4 Sales by Geography

20.3.5 Key Facts

20.3.6 Pipeline Products

20.3.7 Business Strategy

20.3.8 Key Information

20.3.9 SWOT Analysis



List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Retinoblastoma
Exhibit 3: Symptoms: Percentage Occurrence in Patients
Exhibit 4: Techniques Used for Diagnosing Retinoblastoma
Exhibit 5: Intraocular Staging
Exhibit 6: Extraocular Staging
Exhibit 7: Retinoblastoma: Treatment Options
Exhibit 8: Global Retinoblastoma Market 2014-2019 (US$ million)
Exhibit 9: Pipeline Portfolio
Exhibit 10: Global Retinoblastoma Market by Therapeutic Class of Drugs
Exhibit 11: Global Retinoblastoma Market by Disease Status
Exhibit 12: Global Retinoblastoma Market: Percentage Share of Cases (2014)
Exhibit 13: Global Retinoblastoma Market by Geographical Segmentation 2014
Exhibit 14: Baxter
Exhibit 15: Bristol Myers-Squibb
Exhibit 16: GlaxoSmithKline
Exhibit 17: Spectrum Pharmaceuticals
Exhibit 18: Baxter International Inc. : Business Segmentation
Exhibit 19: Baxter International Inc.: Revenue by Business Segmentation 2013
Exhibit 20: Baxter International Inc.: Revenue by Geographical Segmentation 2013
Exhibit 21: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 22: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 23: GlaxoSmithKline: Business Segmentation 2013
Exhibit 24: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 25: GlaxoSmithKline: Sales by Geography 2013
Exhibit 26: GlaxoSmithKline: Pipeline Products 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

Related Market Segments :

Therapy
Chemotherapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.